Angiomax Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review
CONCLUSION: Data from 12 publications and across 36 patients suggests that the use of DOACs in the acute phase of HIT may be a safe and efficacious treatment option with favorable ease of monitoring and management.PMID:38651828 | DOI:10.1093/ajhp/zxae109 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 23, 2024 Category: Drugs & Pharmacology Authors: Cooper Sadowski Justin P Reinert Source Type: research

Ticagrelor vs clopidogrel when coadministered with bivalirudin in patients with acute coronary syndrome undergoing percutaneous coronary intervention
CONCLUSION: As an initial treatment strategy, bivalirudin plus ticagrelor could reduce the 12-month risk of ischemic events compared with bivalirudin plus clopidogrel significantly without increasing the bleeding risk in ACS patients undergoing PCI.PMID:38623472 | PMC:PMC11017352 | DOI:10.1016/j.rpth.2024.102375 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Yang Li Yi Li Miaohan Qiu Yu Xue Kai Xu Yaling Han Source Type: research

Impact of inflammation and steroids on anti-coagulation in children supported on a ventricular assist device
AbstractCritically ill pediatric patients supported on ventricular assist devices (VADs) are increasingly being anticoagulated on bivalirudin, but with difficulty monitoring anticoagulation. Activated partial thromboplastin time (aPTT) has recently been shown to poorly correlate with bivalirudin plasma concentrations, while dTT had excellent correlation. However, aPTT is the more common monitoring test and dTT testing is rarely used. In addition, effects of frequent clinical VAD scenarios (such as inflammation) on the accuracy of aPTT and dTT testing remains uncertain. We reviewed the effects of clinical scenarios (infecti...
Source: Journal of Artificial Organs - April 6, 2024 Category: Transplant Surgery Source Type: research

Bivalirudin: The misunderstood alternative to heparin
Paediatr Anaesth. 2024 Mar 5. doi: 10.1111/pan.14868. Online ahead of print.NO ABSTRACTPMID:38440919 | DOI:10.1111/pan.14868 (Source: Paediatric Anaesthesia)
Source: Paediatric Anaesthesia - March 5, 2024 Category: Anesthesiology Authors: David Faraoni James A DiNardo Source Type: research

Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone
To evaluate the safety of cangrelor administered concurrently with heparin or bivalirudin in patients on mechanical circulatory support. (Source: Journal of Cardiothoracic and Vascular Anesthesia)
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 2, 2024 Category: Anesthesiology Authors: Trent C. Martin, Brittney E. Duewell, Janelle J. Juul, Joseph R.G. Rinka, Lisa Rein, Joel T. Feih Tags: Original Article Source Type: research

Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial
CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03664180.PMID:38406848 | DOI:10.1161/CIRCULATIONAHA.123.067079 (Source: Circulation)
Source: Circulation - February 26, 2024 Category: Cardiology Authors: Yan Yan Jincheng Guo Xiao Wang Guozhong Wang Zeyuan Fan Delu Yin Zhifang Wang Fuchun Zhang Changming Tian Wei Gong Jiamin Liu Jiapeng Lu Yongjun Li Changsheng Ma Eric Vicaut Gilles Montalescot Shaoping Nie RIGHT Investigators Source Type: research

Use of bivalirudin after initial heparin management among adult patients on long ‐term venovenous extracorporeal support as a bridge to lung transplant: A case series
AbstractA growing body of evidence supports the use of bivalirudin as an alternative to unfractionated heparin (UFH) for the prevention of thrombotic events in patients on venovenous (VV) extracorporeal membrane oxygenation (ECMO). However, data in patients bridged to lung transplantation are limited. In this case series, we describe the outcomes of six patients who were transitioned from UFH to bivalirudin during their course of VV ECMO support as a bridge to lung transplantation. All six patients were on VV ECMO support until transplant, with a median duration of 73 days. Bivalirudin demonstrated a shorter time to fir...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 3, 2024 Category: Drugs & Pharmacology Authors: Hala Halawi, Jesse E. Harris, Ahmad Goodarzi, Simon Yau, Jihad G. Youssef, Mena Botros, Howard J. Huang Tags: CASE REPORT Source Type: research